



Circular

2024

Date: 23rd July 2024

Reference no: ASND/BUR/CIR/2024/4

Re: Bulk procurement project

With the establishment of Bulk Procurement process, Aasandha Company will be implementing changes to the prescribing and dispensing of medicines under Aasandha Scheme. This initiative begins with the first phase covering seven registered medicines from July 22, 2024. The revised guidelines for prescribing and dispensing medications under Aasandha are outlined below:

For Prescribers:

- Generic Prescribing:** Prescribers must prescribe medicines using their generic names
- Brand Specification Justification:** If a specific brand is prescribed instead of the generic form, the prescriber must provide a **justification** in the medicine instructions field. Generic prescribing is encouraged unless there is a medical necessity for a particular brand.

Code	Name	Strength	Preparation	Diagnosis	Instructions
M0968	Clofenac	50 mg	Tablet	Pain in joint	BD x 5 days (Dispense only Clofenac - patient has a history of allergic reactions to other brands)

For Pharmacies:

- Dispensing Prioritization:** Pharmacies are required to prioritize dispensing medicines registered under Aasandha that are part of the bulk procurement initiative.
- Brand Dispensing:** If a **medical reason** was indicated by the doctor in the medicine instructions, this specific brand is required to be dispensed to the patient. No rejections will be applied to pharmacies on ensuring the validity of the reasoning.

Aasandha will evaluate the reasons provided by prescribers during this phase and establish a validated list of reasoning standards as an enhancement to the portal.

These directives aim to streamline medication procurement under Aasandha, ensuring high standard medicine availability to the patients through bulk purchasing and encouraging the use of generic medications whenever feasible.

For further inquiries or additional information regarding these changes, please contact our 24/7 hotline at 1400

Medicines related to Bulk Procurement (Phase 1)

Aasandha Code	MFDA Pcode	Product	Generic	Dosage Form	Strength	Manufacturer
B0001	P5935	Tegretol	Carbamazepine	Oral Liquid	100 mg per 5 ml	Novartis Pharmaceuticals Second Floor, the WestWorks Building, White City Place 195 Wood Lane, London, W12 7FQ
B0002	P5934	Tegretol	Carbamazepine	Tablet	200 mg	Novartis Pharmaceuticals Second Floor, the WestWorks Building, White City Place 195 Wood Lane, London, W12 7FQ
B0003	P5930	Ceftriaxone	Ceftriaxone	Injection	1,000 mg	Venus Remedies limited / India Hill Top Industrial Estate, Jharmajri EPIP Phase - 1 (Extn), Bhatoli Kalan Baddi, Distt. Solan (Himachal Pradesh) 173205, India
B0004	P5931	Diclofenac Sodium	Diclofenac Sodium	Tablet	50 mg	MEDREICH PLC Warwick House, Plane Tree Crescent, Feltham TW13 7HF, UK
B0005	P5936	Fluoxetine	Fluoxetine	Capsule	20 mg	Strides Pharma, Unit 4, Metro Centre, Tolpits Lane, Watford, Herts WD18 9SS, United Kingdom
B0006	P5932	Meropenem	Meropenem	Injection	1 g	Anfarm Hellas S.A, 61st km National Road, Athens - Lamia, 32009, Schimatari, Greece
B0007	P5933	Vildagliptin	Vildagliptin	Tablet	50 mg	Milpharm Limited, Ares Block, Odyssey Business Park, West End Road, South Ruislip HA46QD, United Kingdom



[Handwritten signature]